Physician profile
John A Wolfe
NPI 1144287509
$410.17
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $111 · 2021: $85.02.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Haemonetics Corporation | $96.56 | 2019 | |
| Foundation Medicine, INC. | $62.51 | 2019 | |
| Merck Sharp & Dohme LLC | $55.57 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $45.43 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.97 | 2019-2020 | |
| Seagen INC. | $23.28 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $21.32 | 2020 | |
| Taiho Oncology, INC. | $18.95 | 2020 | |
| Amgen INC. | $15.45 | 2021 | |
| Agios Pharmaceuticals, INC. | $15.23 | 2020 | |
| Eisai INC. | $14.90 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.